ELDN
HealthcareEledon Pharmaceuticals, Inc.
$1.65
+$0.03 (+1.85%)
Jan 5, 2026
Price History (1Y)
Analysis
Eledon Pharmaceuticals, Inc. operates in the healthcare sector, within the biotechnology industry. The company has a relatively small scale, with 31 employees. The company's financial health is concerning, with low margins across various profitability metrics: gross margin of 0.0%, operating margin of 0.0%, and profit margin of 0.0%. Additionally, the net income over the trailing twelve months (TTM) was -$82,669,000. Returns on equity and assets were -95.5% and -44.2%, respectively. The company's balance sheet shows a significant amount of cash ($93.40M) but relatively little debt ($722,000), resulting in a debt to equity ratio of 0.79. The valuation context for Eledon Pharmaceuticals is characterized by a negative forward P/E ratio (-1.73). The market cap is $123.81 million. The company does not have a dividend yield or payout ratio listed.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Visit website →Key Statistics
- Market Cap
- $123.81M
- P/E Ratio
- N/A
- 52-Week High
- $4.96
- 52-Week Low
- $1.35
- Avg Volume
- 2.21M
- Beta
- 0.90
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 31